AGIOS PHARMACEUTICALS, INC. SEC Filing

AGIO filed a Form 144 reporting a proposed sale of 4,055 shares of common stock, tied to the vesting of restricted stock units on 03/02/2026.

Accepted by SEC EDGAR 03/02/2026 - 04:08 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AGIO filed a Form 144 reporting a proposed sale of 4,055 shares of common stock, tied to the vesting of restricted stock units on 03/02/2026.

Shares outstanding were 58,592,172 as of 03/02/2026. The filing also lists prior sales of 2,932 shares on 12/30/2025.

Insights

Securities Compliance Analyst

Form 144 notifies the market of a proposed insider sale of 4,055 shares.

The notice records a proposed disposal of 4,055 shares tied to RSU vesting on 03/02/2026. The filing lists prior sales of 2,932 shares on 12/30/2025.

Cash‑flow treatment and buyer details are not provided in the excerpt; subsequent Form 4 or Form 5 may report completed transactions and final proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001881190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AGIOS PHARMACEUTICALS, INC.
SEC File Number	001-36014
Address of Issuer	88 SIDNEY STREET CAMBRIDGE MASSACHUSETTS 02139
Phone	617-649-8600
Name of Person for Whose Account the Securities are To Be Sold	Gheuens Sarah
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4055	122583.00	58592172	03/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/02/2026	Vesting of Restricted Stock Units	Issuer			4055	03/02/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sarah Gheuens 88 Sidney Street Cambridge MA 02139	Common Stock	12/30/2025	2932	79428.00

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/01/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	William Cook, attorney-in-fact for Sarah Gheuens
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)